My two cents:
- Earning growth will be higher from previous quarters in general for Pharma companies due to easing of pricing pressure in US. Complex generic is the place where money can be made.
- In heady days of 2015, pharma companies were considered as defensive stocks. Pharma companies current valuations around 20 is attractive, considering 2015, where they command 70PE also.
My views for upcoming years is highly positive for pharma sector.
Disclosure: Invested in Natco, Aaarti Pharmalabs and Supriya Lifescience
Subscribe To Our Free Newsletter |